ClearNote® Health, a company dedicated to early cancer detection in high-risk individuals, has announced a new partnership with the Pancreatic Cancer Early Detection (PRECEDE) Consortium. The PRECEDE Consortium is an international collaborative group of experts from multiple institutions working together to improve early detection methods for individuals at risk of pancreatic cancer or those with pancreatic cysts through innovative collaboration and data sharing.

The PRECEDE Consortium is currently leading an extensive observational longitudinal prospective cohort study. This study involves the regular collection of biosamples and standard imaging every 6-12 months for people in predefined high-risk categories. Thus far, the study has enrolled over 5,000 participants across 43 global sites.

ClearNote Health's Avantect™ Pancreatic Cancer Test, already available for high-risk patients, including those recently diagnosed with type 2 diabetes, will be used in conjunction with imaging as a surveillance tool for early cancer detection. The primary goal of this partnership is to further validate and expand the use of this molecular test in other high-risk groups.

The Avantect test is a DNA-based blood test that assesses epigenomic levels of the 5-hydroxymethylcytosine (5hmC) biomarker and genomic features to identify abnormal DNA signals associated with early-stage pancreatic cancer or high-grade dysplasia. By utilizing both epigenomic and genomic data from patients' blood samples, ClearNote Health employs machine learning algorithms to create a set of informative cancer biomarkers, enabling the identification of cancer signals through DNA extracted from tumor cells via circulating cell-free DNA (cfDNA).

Source: businesswire.com